Table 1

Gene expression analysis in cell lines by RT-PCR

HOPHOXB9HLXB9HOXB4*mir-196a1
HL
    HD-70NE+NE+NE
    HDLM-2+++++
    KM-H2++++++
    L-1236+++++
    L-428+++++
    L-540++++
    SUP-HD1++++++
ALCL
    DEL++NE
    FE-PDNE+NENE
    KARPAS-299+++
    JB6++NE
    KI-JK++NE
    MAC2A+++NE
    SR-786+++
    SU-DHLINE+NENENE
    SUP-M2++++++
MLBCL
    KARPAS-1106PNE++NE
    MedB-1+++NE
DLCL/FL
    DB+NE
    DOHH2+NE
    KARPAS-422++
    KIS-1NE+
    OCI-LY-19NE+NENE
    RC-K8+++
    RI-1+
    SBH-1+NENE
    SC-1+
    SU-DHL-4NE
    WSU-NHLNE
MCL
    GRANTA-519NE++NE
    JEKO-1+NE
BL
    BL-41+
    BL-70
    DAUDI++
    DG-75NENENE
    NAMALWA+NE
    RAJI++NE
NKTL
    DERL-7++NE
Other BCL
    380NENENE+NE
    AMO-INE++NE
    CI-I+++NE
    CRO-AP3+NE
    JVM-13+NE
    L-591++NE
    LP-1NE
    MC-116++NE
    MUTZ-5NE+NENE
    NALM-6NENENE
    SU-DHL-16
    TANOUENE
    TS-2NENENENE
    U-266++NE
    U-698NENENE
TCL
    ALL-SIL
    CCRF-CEM+
    HD-MAR
    HPB-ALLNE
    KE-37++NE
    MOLT-4NENE+
    MOLT-14+
    PEERNE+NE
    TALL-1+NE
    TALL-104NENENENE
Myeloid
    CMK-1++NE
    GDM-1++++
    HD-MYZNENE
    HL60NE
    HMC-1+NE++
    K-562+NE++NE
    KASUMI-1NE
    KG-1++NE
    M-07e++NE
    MonoMac-1
    MOLM-16+NENENE
    MOLM-17+NE+NE
    MUTZ-2NE
    MUTZ-3NE
    MUTZ-11NENE++
    NB-4
    NOMO-1+NE
    OCIAML2+NE
    TF-1+
    THP-1+NE
    U-937NE
Controls
    CD34++++NE
    MRC-5NENE
    NC-NC+NE
    PBC+++
Solid tumors
    293++NE
    BPH-1NENE
    CAPAN-1NE
    HELA++NE
    HT-1080+NE+NE
    LN-405NE+NENE
    LN-CAPNE+NENE
    NTERA2NE
    PC-3NE++NENE
  • ALCL indicates anaplastic large cell lymphoma; MLBCL, mediastinal large B-cell lymphoma; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; MBCL, mediastinal B-cell lymphoma; BL, Burkitt lymphoma; NKTL, natural killer T-cell lymphoma; BCL, B-cell lymphoma/leukemia; TCL, T-cell leukemia; PBC, peripheral blood cells (PBCs); NE, no tested expression; +, positive expression; ++, strong expression; –, negative expression.

  • * HOXB4 expression was judged quantitatively.

  • Lymphoma/leukemia entities with at least 50% positive tested cell lines.